TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04321577

Intervention type: PROCEDURE
Intervention: Radical surgery
Description: Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
Study: NCT03825549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual audit feedback
Description: Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual audit feedback
Description: Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer comparison feedback
Description: Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer comparison feedback
Description: Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber.
Study: NCT02412371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Veliparib
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Veliparib
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsule for oral administration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
Study: NCT04451967

Intervention type: PROCEDURE
Intervention: thrombolysis
Description: transfer after thrombolysis for STEMI patients within 6h since onset
Study: NCT02760498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Study: NCT00867204

Intervention type: PROCEDURE
Intervention: ERCP
Description: Patients with clinical indication for ERCP were invited to participate in the Study

Intervention type: PROCEDURE
Intervention: ERCP
Description: Patients with clinical indication for ERCP were invited to participate in the Study
Study: NCT05695846

Intervention type: DEVICE
Group type: OTHER
Intervention: externally applied cricoid cartilage pressure
Study: NCT04133909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab is a sterile liquid formulation. It will be administered as a SC injection (100 mg/mL) delivered once every 4 weeks using a pre-filled safety syringe.
Study: NCT01602029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin added to TAU Simvastatin 20mg taken as once daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to TAU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Odansetron plus simvastatin
Description: Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
Study: NCT02656706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02085395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-T100 ® Gel
Study: NCT05520372

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous immune enhancement therapy (AIET) for cancer patients
Description: Autologous NK cell and CD8 T cell therapy for cancer patients
Study: NCT02437201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liberty Program
Study: NCT04206657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg KHK7580
Description: Single oral dose administration of 1mg KHK7580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3mg KHK7580
Description: Single oral dose administration of 3mg KHK7580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6mg KHK7580
Description: Single oral dose administration of 6mg KHK7580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12mg KHK7580
Description: Single oral dose administration of 12mg KHK7580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6mg KHK7580 for 8days
Description: multiple oral dose administration of 6mg KHK7580 for 8days
Study: NCT04229264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Oral Apixaban 2.5 mg twice daily for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: Acetil Salicilic Acid 100mg once daily for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: Acetil Salicilic Acid 100mg once daily for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75mg once daily for 3 months
Study: NCT02296333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: 8 mg intravenous in the skin closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic
Description: 8 mg intravenous in the skin closure
Study: NCT02828787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night.

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night.
Study: NCT02604875

Intervention type: OTHER
Intervention: observation
Description: blood sampling during 24 hours
Study: NCT00466375

Intervention type: GENETIC
Intervention: Cheek cell samples or blood sample (4mL)
Description: DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.

Intervention type: GENETIC
Intervention: Cheek cell sample or blood sample (4mL)
Description: DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
Study: NCT03465904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Cefaly® Abortive Program device
Description: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cefaly® Abortive Program device
Description: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.
Study: NCT00766545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: oral tablet 100 mg, twice daily, over 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of cilostazol
Description: oral tablet, 0 mg twice daily, over 1 year
Study: NCT02317432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison of a combined CBT + exercise intervention and enhanced usual care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of a combined CBT + exercise intervention and enhanced usual care
Study: NCT06611046

Intervention type: OTHER
Intervention: organ donor
Description: Observational study with sample collection of serum, liver tissue and perfusate fluid from liver donors. No specific interventions were done to the donors as part of the study. The samples were analyzed for specific microNA expression by RT-qPCR.~\*Control group: only serum samples were collected from this group.

Intervention type: OTHER
Intervention: organ donor
Description: Observational study with sample collection of serum, liver tissue and perfusate fluid from liver donors. No specific interventions were done to the donors as part of the study. The samples were analyzed for specific microNA expression by RT-qPCR.~\*Control group: only serum samples were collected from this group.

Intervention type: OTHER
Intervention: organ donor
Description: Observational study with sample collection of serum, liver tissue and perfusate fluid from liver donors. No specific interventions were done to the donors as part of the study. The samples were analyzed for specific microNA expression by RT-qPCR.~\*Control group: only serum samples were collected from this group.

Intervention type: OTHER
Intervention: organ donor
Description: Observational study with sample collection of serum, liver tissue and perfusate fluid from liver donors. No specific interventions were done to the donors as part of the study. The samples were analyzed for specific microNA expression by RT-qPCR.~\*Control group: only serum samples were collected from this group.
Study: NCT04064398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration of gastric residuals
Description: Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
Study: NCT04657068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
Study: NCT06729476

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uroshield vibrator device
Description: UROSHIELDTM is a small device that generates low-energy surface acoustic waves, which transmit energy to the endotracheal tube through a thin cable attached to the tube. Laboratory studies using catheterized urinary tract models have shown a significant reduction in microbial colonization and reduced development of antimicrobial resistance in UROSHIELDTM device treated individuals.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Uroshield vibrator device
Description: UROSHIELDTM is a small device that generates low-energy surface acoustic waves, which transmit energy to the endotracheal tube through a thin cable attached to the tube. Laboratory studies using catheterized urinary tract models have shown a significant reduction in microbial colonization and reduced development of antimicrobial resistance in UROSHIELDTM device treated individuals.
Study: NCT06729658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar
Description: Experimental group participants will receive Madopar 125mg for 6 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group participants will receive placebo for 6 days.
Study: NCT03218748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Honest, Open, Proud (HOP)
Description: Three lessons, one for each two-hour session plus one booster session~1. Considering the pros and cons of disclosure:~   Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure~2. Different ways to disclose:~   Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure~3. Telling one's story:~   Practice how to tell one's story, identifying peers who might be helpful with the coming out process~4. Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience
Study: NCT03640572

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone marrow analysis to identify disseminated tumour cells
Description: Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone marrow analysis to identify disseminated tumour cells
Description: Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
Study: NCT03065257

Intervention type: PROCEDURE
Intervention: Endoscopic Resection
Description: Any Endoscopic resection for Gastrointestinal disorders including neoplasms.